Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
| ▸ | TAS2R31 | P59538 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6556315 | 1.00 | IDO1 (0.43) | IDO1ACHEALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL6556312 | 1.00 | IDO1 (0.43) | IDO1ACHEALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL6556331 | 0.90 | IDO1 (0.41) | IDO1ACHECYP3A4HTR2C | |
| SCHEMBL6556322 | 0.90 | IDO1 (0.41) | IDO1ACHECYP3A4HTR2C | |
| SCHEMBL6556326 | 0.90 | IDO1 (0.41) | IDO1ACHECYP3A4HTR2C | |
| SCHEMBL13213819 | 0.90 | IDO1 (0.41) | IDO1ACHECYP3A4HTR2C | |
| SCHEMBL6556422 | 0.87 | IDO1 (0.58) | IDO1ALDH1A1KDM4ESMN1; SMN2PTGS2 | |
| SCHEMBL6556426 | 0.87 | IDO1 (0.58) | IDO1ALDH1A1KDM4ESMN1; SMN2PTGS2 | |
| SCHEMBL6556416 | 0.87 | IDO1 (0.58) | IDO1ALDH1A1KDM4ESMN1; SMN2PTGS2 | |
| Fumaric Acid SCHEMBL6556498 | 0.81 | IDO1 (0.52) | IDO1ALDH1A1KDM4ESMN1; SMN2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6310208-B1 | Serotonin receptor binding benzo[e]isoindoles and benzo[h]isoquinolines | HOFFMANN-LA ROCHE INC. | 2001-10-30 | — | — | US | claimed |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-08-27 | — | — | US | disclosed |
| US-9079907-B2 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-14 | — | — | US | disclosed |
| EP-2789338-A2 | Condensed pyridine derivate and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2014-10-15 | — | — | EP | disclosed |
| EP-2742936-A1 | Fused heterocyclic compound and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-20140155369-A1 | PREVENTIVES/REMEDIES FOR STRESS URINARY INCONTINENCE AND METHOD OF SCREENING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-06-05 | — | — | US | disclosed |
| EP-2727585-A1 | In-vivo screening method | Takeda Pharmaceutical Company Limited (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-20120253036-A1 | AGENT FOR TREATING FIBROMYALGIA | ASTELLAS PHARMA INC. (JP) | 2012-10-04 | — | — | US | disclosed |
| US-20120165312-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SHIRAI JUNYA (JP) | 2012-06-28 | — | — | US | disclosed |
| US-8158617-B2 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20090131402-A1 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-05-21 | — | — | US | disclosed |
| US-20090131402-A1 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-05-21 | — | — | US | disclosed |
| EP-2018863-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-01-28 | — | — | EP | disclosed |
| US-20070274913-A1 | Preventives/Remedies for Stress Urinary Incontinence and Method of Screening the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| US-20070274913-A1 | Preventives/Remedies for Stress Urinary Incontinence and Method of Screening the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1792629-A1 | PREVENTIVES/REMEDIES FOR STRESS URINARY INCONTINENCE AND METHOD OF SCREENING THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2007-06-06 | — | — | EP | disclosed |
| EP-0958285-B1 | TRICYCLIC BENZO[e]ISOINDOLES AND BENZO[h]ISOQUINOLINES | HOFFMANN LA ROCHE (CH) | 2004-01-07 | — | — | EP | disclosed |
| US-6310208-B1 | Serotonin receptor binding benzo[e]isoindoles and benzo[h]isoquinolines | HOFFMANN-LA ROCHE INC. | 2001-10-30 | — | — | US | disclosed |
| EP-0958285-A1 | TRICYCLIC BENZO[e]ISOINDOLES AND BENZO[h]ISOQUINOLINES | F.HOFFMANN-LA ROCHE AG (CH) | 1999-11-24 | — | — | EP | disclosed |
| WO-1998030546-A1 | TRICYCLIC BENZO[e]ISOINDOLES AND BENZO[h]ISOQUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155369-A1 | PREVENTIVES/REMEDIES FOR STRESS URINARY INCONTINENCE AND METHOD OF SCREENING THE SAME | ADRA2C, HTR2C, HTR3A | IDO1 623/4885ACHE 12/4885ALDH1A1 583/4885 |
| US-20120165312-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | HTR2C, HTR3C, HTR3B | IDO1 363/4885ACHE 906/4885ALDH1A1 822/4885 |
| US-20090131402-A1 | Fused heterocyclic compound and use thereof | HTR2C, HTR3C, HTR3B | IDO1 363/4885ACHE 906/4885ALDH1A1 822/4885 |
| US-20120253036-A1 | AGENT FOR TREATING FIBROMYALGIA | HTR2A, HTR2C, HTR3A | IDO1 1808/4885ACHE 588/4885ALDH1A1 2697/4885 |
| US-20070274913-A1 | Preventives/Remedies for Stress Urinary Incontinence and Method of Screening the Same | ADRA2C, HTR2C, HTR3A | IDO1 623/4885ACHE 12/4885ALDH1A1 583/4885 |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | HTR2C, HTR3C, HTR3B | IDO1 363/4885ACHE 906/4885ALDH1A1 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.